IgG glycosylation profile and the glycan score are associated with type 2 diabetes in independent Chinese populations: A case-control study by Wu, Zhiyuan et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
1-1-2020 
IgG glycosylation profile and the glycan score are associated with 
type 2 diabetes in independent Chinese populations: A case-
control study 
Zhiyuan Wu 
Haibin Li 
Di Liu 
Lixin Tao 
Jie Zhang 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Medicine and Health Sciences Commons 
10.1155/2020/5041346 
Wu, Z., Li, H., Liu, D., Tao, L., Zhang, J., Liang, B., ... & Wang, W. (2020). IgG glycosylation profile and the glycan score 
are associated with type 2 diabetes in independent Chinese populations: a case-control study. Journal of Diabetes 
Research, 2020. https://doi.org/10.1155/2020/5041346 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/8444 
Authors 
Zhiyuan Wu, Haibin Li, Di Liu, Lixin Tao, Jie Zhang, Baolu Liang, Xiangtong Liu, Xiaonan Wang, Xia Li, 
Youxin Wang, Wei Wang, and Xiuhua Guo 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/8444 
Research Article
IgG Glycosylation Profile and the Glycan Score Are
Associated with Type 2 Diabetes in Independent Chinese
Populations: A Case-Control Study
Zhiyuan Wu ,1 Haibin Li ,1 Di Liu,1 Lixin Tao,1 Jie Zhang ,1 Baolu Liang ,1
Xiangtong Liu ,1 Xiaonan Wang,1 Xia Li ,2 Youxin Wang ,1 Wei Wang ,1,3
and Xiuhua Guo 1
1Beijing Municipal Key Laboratory of Clinical Epidemiology, Department of Epidemiology and Health Statistics, School of
Public Health, Capital Medical University, Beijing, China
2Department of Mathematics and Statistics, La Trobe University, Australia
3Department of Public Health, School of Medical and Health Sciences, Edith Cowan University, Perth, Australia
Correspondence should be addressed to Xiuhua Guo; statguo@ccmu.edu.cn
Received 17 January 2020; Revised 18 March 2020; Accepted 19 May 2020; Published 9 June 2020
Academic Editor: Patrizio Tatti
Copyright © 2020 Zhiyuan Wu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. The relationship between the IgG glycan panel and type 2 diabetes remains unclear in Chinese population. We aimed
to investigate the association of the IgG glycan profile and glycan score with type 2 diabetes.Methods. In the discovery population,
162 individuals diagnosed with type 2 diabetes and 162 matched controls from Beijing health management cohort were included.
We analyzed the IgG glycan profile and composed a glycan score for type 2 diabetes. Findings were validated in the replication
population from Beijing Xuanwu community cohort (280 cases and 508 controls). Area under curve (AUC) using 10-fold and
bootstrap validation, net reclassification index (NRI), and integrated discrimination index (IDI) were calculated for the glycan
score. Results. In the discovery population, 5 initial IgG glycans and 7 derived traits were significantly associated with type 2
diabetes after Bonferroni correction and Lasso selection, which were validated in the replication population subsequently. The
glycan score composed of these IgG glycans and traits showed a strong association with type 2 diabetes (combined odds ratio
(OR): 3.78) and its risk factors. In the replication population, AUC of the model involving clinical traits improved from 0.74 to
above 0.90, and the values of NRI and IDI were 0.35 and 0.42, respectively, with the glycan score added. Conclusions. IgG
glycosylation profiles were associated with type 2 diabetes and the glycan score may be a novel indicator for diabetes which
reflected a proinflammatory status.
1. Background
Type 2 diabetes is a complex and chronic metabolic disease
characterized by hyperglycemia and insulin resistance [1].
Type 2 diabetes has represented an extremely threatening
public health issue, with a gradually increasing prevalence
(projected to rise from 171 million in 2000 to 366 million
in 2030) and many severe complications [2]. However, its eti-
ological mechanism remains unclear.
Both genetic and environmental factors play a crucial role
in the disease pathophysiology [3], among which glycosyla-
tion is one of the most common and substantial posttran-
scriptional modifications with various glycosyltransferases
involved in. The N-oligosaccharides of glycoproteins exert
important biological functions involving cellular recognition
and molecular signal regulation [4]. Many proteins are
modified by these glycans, and the variation of IgG gly-
cans has been most widely described. Biantennary glycans
are covalently attached at the Fc region of each heavy
chain of IgG [5]. Notably, the attached glycans regulate
the stability of IgG and its effector functions [6], involving
antibody-dependent cell-mediated cytotoxicity (ADCC) [7]
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and complement-dependent cytotoxicity (CDC) [8]. The
IgG glycans are emerging as potential biomarkers of vari-
ous diseases, such as rheumatoid arthritis [9], ischemic
stroke [10], dyslipidemia [11], kidney disease in type 1
diabetes [12], and many cancers [13–15].
Type 2 diabetes is accompanied by glucose metabolic dis-
order and proinflammatory status [16] while the specific IgG
glycan could switch its role between pro- and anti-
inflammatory functions. Meanwhile, the variation of IgG gly-
cans has been linked to various clinical risk factors of type 2
diabetes, such as body mass index (BMI), blood pressure, and
dyslipidemia [11, 17]. Recently, the inflammatory-related
functions of IgG glycans in type 2 diabetes and fasting blood
glucose (FBG) abnormality have been reported in European
[18] and Chinese populations [19]. Although both studies
have identified some type 2 diabetes-specific or FBG-
specific IgG glycans, the solitary glycan presented only a rel-
atively small and unstable association with disease status. The
disease variation that the solitary glycan could explain was
very limited.
We hypothesized that the IgG glycan score could inte-
grally and robustly evaluate the status of type 2 diabetes
[20]. Hence, this study is aimed at investigating the associa-
tion of the IgG glycan profile and glycan score with type 2
diabetes in a matched case-control cohort, followed by vali-
dation in another independent Chinese population.
2. Methods
2.1. Study Design and Population. All 162 new cases of diabe-
tes between Dec 2014 and Jun 2016 and 162 matched con-
trols, from the Beijing health management cohort, were
enrolled in the discovery population. The Beijing health
management cohort is an ongoing population-based study
of participants aged ≥18 years for metabolism-related disease
research [21]. 280 cases and 508 natural controls, from the
Beijing Xuanwu community cohort [19], were recruited in
the replication population according to the inclusion and
exclusion criteria. All the participants in this study were
asked to participate in clinical measures (physical and bio-
chemical examinations), and the fasting blood samples were
also taken. Participants were required to meet the following
inclusion criteria: (1) signed informed consent prior to par-
ticipation, (2) at least 18 years old, and (3) enough clinical
data to judge the type 2 diabetes status. Individuals were
excluded based on the following criteria: (1) pregnant or lac-
tating women, (2) history of mental illness or infectious
disease, and (3) history of other types of diabetes, cardio-
cerebrovascular diseases, liver disease, renal failure, cancers,
or autoimmune diseases. This study was approved by the
Capital Medical University Ethics Committee and conducted
according to the principles of the Declaration of Helsinki.
Written informed consent was obtained at the beginning of
the study.
2.2. Measurement of Blood Glucose. The blood glucose con-
centrations were measured by the glucose oxidase-peroxidase
method (Mind Bioengineering Co. Ltd., Shanghai, China).
The FBG was defined as the glucose concentrations before
breakfast after overnight fasting (no food, except drinking
water, for at least 8-10 hours), while two-hour postprandial
blood glucose (PBG) was measured after 2 hours from the
beginning of meals. Both FBG and PBG are commonly used
in clinical diabetes diagnosis, reflecting the functional reserve
of islet beta cells. Type 2 diabetes was diagnosed by physicians
according to the ADA and WHO criteria as follows: FBG ≥
7:0mmol/L, PBG ≥ 11:1mmol/L, or regular use of antidia-
betes drugs.
2.3. Covariates. The demographic characteristics (age and
sex) of participants were collected by questionnaires. Weight
and height measurements were carried out in the physical
examination. The BMI was calculated by the formula
weight ðin kilogramsÞ/height2 ðinmeters squaredÞ; the nor-
mal range was defined as 18:5 ≤ BMI < 24:0 (kg/m2) accord-
ing to the WHO criteria for the Asian population. Systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
were measured twice on the right arm using a standard mer-
cury sphygmomanometer after the subjects had rested at
least 10min in a sitting position. High blood pressure
(HBP) was defined as SBP ≥ 140 or DBP ≥ 90 according to
the WHO standard. Serum total cholesterol (TC) and high-
density lipoprotein cholesterol (HDL-cholesterol) were mea-
sured with an Olympus Automatic Biochemical Analyzer
(Hitachi 747; Tokyo, Japan). Non-high-density lipoprotein
cholesterol (nonHDL-cholesterol) was defined as the differ-
ence between TC and HDL-cholesterol.
2.4. IgG Glycosylation Analysis. IgG glycan analyses were
conducted on participants both in the discovery and replica-
tion populations. IgG isolation, glycan release, labeling, and
detection were executed as described previously [22]. Briefly,
IgG protein was isolated from diluted plasma using 96-well
protein G monolithic plates, washed in 1x phosphate-
buffered saline (PBS), eluted with 0.1M formic acid, and
neutralized with 1M ammonium bicarbonate. Dried IgG
was denatured with 30μL sodium dodecyl sulfate (SDS)
and 10μL Igepal-CA630 (4%). The glycans were released
with 2 units of PNGase F in 10μL 5x PBS and incubated
at 37°C for 20h. Right after the completion of this step,
released glycans were labeled with 35μL 2-AB at 65°C for
3 h and then purified, washed, and eluted using hydrophilic
interaction liquid chromatography solid phase extraction.
Finally, 24 IgG glycan peaks (GP) were measured by using
an ultra-performance liquid chromatography platform
(Waters, America); the structures of GPs were reported
previously [18].
In both populations, the plasma samples were detected
in the same manner into 24 peaks, and each glycan
amount was expressed as the percentage of the total inte-
grated peak area. An additional 54 derived glycan traits
(IGP) describing the relative abundances of galactosylation,
sialylation, bisecting N-acetylglucosamine (GlcNAc), core
fucosylation, and mannose were calculated from the 24
directly measured GPs. IgG glycan expressions were nor-
malized followed by log transformation and batch-effect
correction.
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2.5. Statistical Analysis. Continuous variables adhering to the
normal distribution were represented as the mean ±
standard deviation ðSDÞ; otherwise, the interquartile range
(P25-P75) was substituted. The differences of continuous var-
iables between the two groups were tested by the independent
sample t tests or the Mann–Whitney tests. Categorical vari-
ables were represented as n (proportion), and the differences
were tested by the chi-square tests. Data analysis was per-
formed using SAS software (version 9.2). All reported P
values were two-tailed, and P < 0:05 was considered statisti-
cally significant.
Propensity score matching (PSM) was used in the discov-
ery cohort to match controls (1 : 1) for the type 2 diabetes
patients. 342 subjects (162 cases and 162 controls) were
recruited after age, sex, and BMI were considered in the
PSM model. Logistics regression models were used to inves-
tigate the associations of the initial IgG glycans and derived
traits with type 2 diabetes. Bonferroni correction was applied
for 78 tests, and P values < 6.41E-4 were considered statisti-
cally significant. The IgG glycans and derived traits both
selected by logistics model and lasso model were used to
compose the glycan score with coefficients set by lasso regres-
sion model. The formula of this glycan score is as follows:
Score = −0:124 ∗GP3 − 0:428 ∗GP5 − 0:093 ∗GP20 + 0:249
∗GP22 + 0:110 ∗GP24 + 0:520 ∗ IGP32 + 0:334 ∗ IGP42 +
0:152 ∗ IGP45 − 0:584 ∗ IGP46 − 0:316 ∗ IGP47 + 0:380 ∗
IGP60 − 0:125 ∗ IGP69.
Subsequently, the results of the primary analyses were
validated in an independent replication population. All the
analyses presented above were performed using R (version
3.3.2) packages: MatchIt and glmnet.
In addition, the discrimination capacity of the glycan
score was evaluated in the replication population. Three
models were considered: model 1, involving the clinical traits
(age, sex, BMI, HBP, HDL-cholesterol, nonHDL-choles-
terol); model 2, involving the glycan score; and model 3,
involving the combination of the clinical traits and the glycan
score. For prediction analyses (to infer an outcome given the
covariates in the statistical sense), we fitted the logistic
models with 10-fold cross-validation and bootstrap strategy.
In 10-fold cross-validation, the whole samples were ran-
domly divided into 10 subgroups, where one subgroup served
as the testing set and the other 9 subgroups served as the
training set. This process was repeated for all folds, and the
average value of area under curve (AUC) was calculated. In
bootstrap validation, we obtained distinct data sets by repeat-
edly sampling observations from the original data set, rather
than repeatedly obtaining independent data sets from the
population, thus to provide an estimate of the accuracy and
quantify the uncertainty of the logistic models [23]. We also
computed the value of net reclassification index (NRI) and
integrated discrimination index (IDI) to compare the models
with and without the glycan score. NRI focused on reclassifi-
cation tables constructed separately for subjects with and
without events and quantified the correct movement in clas-
sification for models with and without the new marker, while
IDI quantified jointly the overall improvement in sensitivity
and specificity over all possible cut-offs [24]. All the analyses
presented above were performed using the R packages:
pROC, fproc, cvAUC, and predictABEL.
3. Results
3.1. Participant Characteristics. In the discovery population,
162 cases with type 2 diabetes and 162 matched controls were
included. The controls were selected according to age, sex,
and BMI. In the replication population, 280 cases with type
2 diabetes and 508 natural controls were recruited. The char-
acteristics of the subjects in the discovery population and
replication population are presented in Table 1.
3.2. Associations of the IgG Glycan Score with Type 2 Diabetes.
Detailed IgG glycan structures were reported previously [25],
and the characteristics of each structure was explained in
Table 1: The characteristics of participants in the discovery and replication populations.
Overall Controls Type 2 diabetes P value
Discovery population n = 324 n = 162 n = 162
Age (years)a 51.40 (±7.65) 51.39 (±7.35) 51.41 (±7.97) 0.997
Sex (male/female)b 72/252 36/126 36/126 1.000
BMI (<18.5/18.5~23.9/>23.9)b 1/69/254 0/35/127 1/34/127 0.602
HBP (yes/no)b 101/223 55/107 46/116 0.337
HDL-cholesterol (mmol/L)c 1.13 (1.10-1.57) 1.45 (1.25-1.65) 1.19 (1.04-1.37) <0.001
nonHDL-cholesterol (mmol/L)c 3.50 (2.92-4.10) 3.62 (3.06-4.15) 3.29 (2.75-3.95) 0.007
Replication population n = 788 n = 508 n = 280
Age (years)a 49.92 (±7.75) 42.15 (±9.77) 64.00 (±6.73) <0.001
Sex (male/female)b 338/450 91/417 247/33 <0.001
BMI (<18.5/18.5~ 23.9/>23.9)b 26/318/444 26/277/205 0/41/239 <0.001
HBP (yes/no)b 144/644 58/450 86/194 <0.001
HDL-cholesterol (mmol/L)c 1.53 (1.25-1.79) 1.68 (1.47-1.86) 1.21 (1.04-1.44) <0.001
nonHDL-cholesterol (mmol/L)c 3.22 (2.64-3.76) 3.30 (2.84-3.83) 2.98 (2.29-3.58) <0.001
aMean (±SD) is given; bnumbers of each category are given; cmedian (P25-P75) is given.
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Supplementary Table S1. Table 2 showed that the 12 IgG
glycans were significantly associated with type 2 diabetes in
the discovery population which were subsequently validated
in the replication population. The boxplots of these 12 IgG
glycans in the discovery population and replication
population are presented in Figure 1. After that, the 12
glycans were used to compose the glycan score, among
which 6 glycans were increased and 6 were decreased in the
type 2 diabetes cases. The OR and P values were combined
with meta-analysis using the weighted z-transform method.
A higher glycan score was associated with a stronger
probability of type 2 diabetes, and the combined OR value
was 3.78 (95% CI: 3.07-4.49). The coefficients and P values
of all the 78 IgG glycans were shown in Supplementary
Table S2.
Figure 2 illustrated the contribution of each IgG glycan to
the glycan score and the correlation with clinical traits which
were also the risk factors of type 2 diabetes. Both in the dis-
covery and replication populations, the glycan score pre-
sented significant univariate associations with all these
clinical traits consistently (all P values < 0.001), while posi-
tively correlated with SBP, FBG, and PBG and negatively cor-
related with DBP, HDL-cholesterol, and nonHDL-cholesterol.
3.3. Discrimination Capacity of the IgG Glycan Score for Type
2 Diabetes. The discrimination capacity of the glycan score
was evaluated in the replication population, and the AUC
values for the clinical traits, the glycan score, and their com-
bination are shown in Table 3. Adding the glycan score to the
model containing the clinical traits could significantly
improve the discrimination capacity (bootstrap: 0.742 vs.
0.918; 10-fold cross-validation: 0.744 vs. 0.923) while the
NRI and IDI were 0.350 (95% CI: 0.241-0.458, P < 0:001)
and 0.421 (95% CI: 0.398-0.493, P < 0:001), respectively.
There was a statistically significant difference between the
AUC values of the clinical variables with and without the gly-
can score (P < 0:001). However, the AUC values of the glycan
score with and without the clinical variables were similar
(P = 0:08) which implied the glycan score could reflect the
clinical characteristics to some extent.
Table 2: Associations of the IgG glycans and glycan score for type 2 diabetes in the discovery and replication populations and meta-analyses.
Glycan peak Glycan structurea
Discovery
population
(n = 324)
Replication
population
(n = 788)
Meta-analyses
OR P valueb OR P valueb OR P valueb
Upregulated
GP22 A2BG2S2 2.520 <0.0001 2.535 <0.0001 2.531 <0.0001
GP24 FA2BG2S2 3.611 <0.0001 3.533 <0.0001 3.556 <0.0001
IGP32 FBG2S2/(FBG2+FBG2S1+FBG2S2) 5.392 <0.0001 8.717 <0.0001 6.621 <0.0001
IGP42 GP2n 1.542 0.0003 3.826 <0.0001 1.913 <0.0001
IGP45 GP6n 1.793 <0.0001 5.668 <0.0001 2.132 <0.0001
IGP60 FG1n total/G1n 4.038 <0.0001 4.551 <0.0001 4.349 <0.0001
Downregulated <0.0001
GP3 A2B 0.392 <0.0001 0.351 <0.0001 0.361 <0.0001
GP5 M5 0.106 <0.0001 0.021 <0.0001 0.026 <0.0001
GP20 FA2FG2S1 0.158 <0.0001 0.017 <0.0001 0.020 <0.0001
IGP46 GP7n 0.232 <0.0001 0.183 <0.0001 0.195 <0.0001
IGP47 GP8n 0.510 <0.0001 0.272 <0.0001 0.313 <0.0001
IGP69 FBG2n/G2n 0.350 <0.0001 0.486 <0.0001 0.435 <0.0001
Glycan score — 3.309 <0.0001 7.145 <0.0001 3.782 <0.0001
aStructure abbreviations: F: core fucose; A: number of antennas; B: bisecting GlcNAc; M: number of mannose residues; Gx: number of galactoses; Sx: number of
sialic acids linked to galactose; n: neutral glycans. bP values < 6.41E-4 was considered statistically significant.
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Figure 1: Distribution of IgG glycan peaks and traits associated
with type 2 diabetes. Upper half: distribution of glycans in the
discovery population. Bottom half: distribution of glycans in the
replication population. This figure shows the relative expression of
each glycan for controls (blue) and cases (red).
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4. Discussion
In this study, we described the association of the IgG glycan
profile and glycan score with type 2 diabetes in Chinese pop-
ulation. We found and replicated that GP3, GP5, GP20,
GP22, GP24, and several IgG-derived traits could compose
a glycan score to discriminate the type 2 diabetes individuals
from the health controls effectively for the first time. Addition-
ally, the glycan score was also correlated with some clinical
traits, reflecting the influence of these clinical factors partly.
Notably, the AUC of the IgG glycan score along for type 2 dia-
betes was above 0.90 using10-fold and bootstrap validation.
Type 2 diabetes is a polygenic and multifactorial disease
in which genetic and environmental factors interact [16, 26]
while the IgG glycans could reflect both the genetic and post-
transcriptional modifications [27–29]. The changes of IgG
glycans have been reported to be associated with various dis-
eases, involving rheumatoid arthritis, cancers, and many
chronic metabolic diseases [28]. In this study, we found that
GP3, GP5, and GP20 were increased in the type 2 diabetes
individuals while GP22 and GP24 were decreased. The
changes of directly measured IgG glycans were in accordance
with an increase of structures with bisecting GlcNac, a high
percentage of disialylation, and a decrease of simple glycan
structures. Meanwhile, the derived traits associated with type
2 diabetes reflected an increase of complex structures (bian-
tennary glycan structures in total neutral IgG glycans and
disialylation of fucosylated digalactosylated structures with
bisecting GlcNAc), an increase of high mannose structures,
a decrease of monogalactosylation structures, and a low per-
centage of fucosylation in digalactosylated structures with
and without bisecting GlcNAc.
The results were largely in line with previous studies of
IgG glycans and total serum/plasma protein glycomics pro-
file in type 2 diabetes or its risk factors [10–12, 17, 30–33].
Previous studies have shown that complex glycan structures
(IGP32 and IGP42) were excessively expressed in response
to some inflammatory diseases, such as ulcerative colitis
[34] and type 1 diabetes [30]. Individuals with type 2 diabetes
also suffered from the chronic inflammation, and IgG pro-
teins were sensitive to physical inflammatory stress. There-
fore, the evaluated proportion of multibranched and
complex glycan structures may be induced by the chronic
inflammation. Additionally, the presence of bisecting
GlcNAc [35] and lack of core fucosylation [36] were thought
to strengthen the ADCC effect of IgG, while the decreased
percentage of galactosylation (accompanied by lowered per-
centage of disialylation) could magnify the CDC effect, thus
strengthening its proinflammatory function [37, 38]. These
changes indicated the glycan score could represent a
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Figure 2: Composition of the IgG glycan score and its correlations with clinical traits in the discovery and replication populations. Red:
positively correlated with the glycan score; blue: negatively correlated with the glycan score; FBG: fasting blood glucose; PBG: two-hour
postprandial blood glucose; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL-cholesterol: high-density lipoprotein
cholesterol; nonHDL-cholesterol: non-high-density lipoprotein cholesterol.
Table 3: AUCs of discrimination models calculated using bootstrap validation and 10-fold cross-validation in the replication population.
Bootstrap (n = 1000) Cross-validation (10-fold)
AUC Std error 95% CI AUC Std error 95% CI
Model 1 0.742 0.023 0.683-0.828 0.744 0.024 0.690-0.811
Model 2 0.902 0.018 0.881-0.943 0.916 0.018 0.883-0.949
Model 3 0.918 0.015 0.890-0.949 0.923 0.014 0.900-0.954
Model 1: clinical traits (age, sex, BMI, HBP, HLDL-cholesterol, nonHDL-cholesterol) included; model 2: glycan score included; model 3: clinical traits and
glycan score included.
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proinflammatory signal in type 2 diabetes. Similarly, Lemmers
et al. reported the IgG glycan patterns associated with type 2
diabetes based on a European population and found a decrease
of galactosylation and sialylation structures, a decrease of
fucosylated structures without bisecting GlcNAc, and an
increase of fucosylated structures with bisecting GlcNac [18].
In our study, decreased galactosylation (GP8n) was also
observed. However, the proportions of fucosylated structures
with (GP7n, FA2BG2S1) and without (FA2FG2S1) bisecting
GlcNAc both decreased. Therefore, the role of fucosylation
in structures with and without bisecting GlcNAc for type 2
diabetes warrants further investigation. In addition, we found
an increased level of high mannose glycan structures in total
neutral IgG glycans (GP6n) which was not previously
reported in type 2 diabetes. High mannose of IgG glycans
were reported to enhance the ADCC effect and exert a proin-
flammatory function [39, 40]. The role of IgG glycans with
high mannose in type 2 diabetes needs to be further studied.
The strength of our study was that we explored the IgG
glycan profile of type 2 diabetes in Chinese population and
we composed and validated the glycan score to discriminate
the type 2 diabetes individuals from healthy controls. The gly-
can score could comprehensively reflect the IgG glycan
changes of type 2 diabetes than solidary glycan. Additionally,
the glycan score was strongly associated with type 2 diabetes
with a combined OR of 3.78. Meanwhile, the glycan score
was correlated with several clinical traits which were also the
risk factors of type 2 diabetes, and it could reflect more infor-
mation than these clinical traits. The AUC of model involving
clinical traits improved from 0.74 to 0.90 when the glycan
score added. However, the results should be interpreted in
the context of some limitations. First, the case-control design
could lead to an overestimation of the AUC of the ROC curve,
and we could not claim an casual correlation. Also, due to the
lack of prospective follow-up, we could not exclude that sev-
eral individuals of the control population would develop type
2 diabetes by the time they reach the age of the cases, as the
controls were substantially younger than the cases in the rep-
lication population. Second, we failed to collect the medication
information of the cases, and the antidiabetics medication
could affect glucose level, thus having a potential effect on
the glycosylation pattern. Third, our study focused on the Chi-
nese population, and more collaborations were needed to cre-
ate a larger sample size and ensure population representation.
5. Conclusions
The IgG glycan score was associated with type 2 diabetes that
reflected a proinflammatory status. These findings implied
that the glycan score may be a potential and comprehensive
indicator for type 2 diabetes and complex inflammatory sta-
tus which warrants further investigation.
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